This sub-license will allow Mayo Clinic to add ABL kinase domain mutation testing to the current range of BCR-ABL analyses in the molecular hematopathology laboratory, thus providing critical information to clinicians about possible drug resistance in chronic myelogenous patients receiving tyrosine kinase inhibitor therapy.
The ability to offer ABL kinase domain mutation testing is expected to help guide Mayo physicians regarding the best course of treatment for these patients.
The intellectual property for the sub-license is based on a US patent owned by Oregon Health & Science University (OHSU). MolecularMD was granted a license in 2007 for the exclusive commercial rights of the patented mutation discoveries made by Brian Druker and Amie Corbin at OHSU.